Glyburide Tablet shortage
Glyburide Tablet is currently listed in shortage by the FDA. The FDA lists 4 affected products. This page was last refreshed from FDA data on Sep 22, 2026.
Sanofi-Aventis is permanently discontinuing its glyburide tablets. Other manufacturers, including Teva and Heritage Pharmaceuticals, still list glyburide in 1.25 mg, 2.5 mg, and 5 mg tablets as available.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Glyburide Tablet. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Aug 10, 2026Currently in shortage4 of 4 products affected.
-
Aug 10, 2026First reported to the FDA4 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Sanofi-Aventis U.S. LLC 📞 800-633-1610 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Diabeta, Tablet, 2.5 mg (NDC 0093-9433-01) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Diabeta, Tablet, 1.25 mg (NDC 0093-9477-53) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Diabeta, Tablet, 5 mg (NDC 0093-9364-01) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Diabeta, Tablet, 5 mg (NDC 0093-9364-10) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
These rows are manufacturer reports to the FDA for Glyburide Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Glyburide Tablet? options further down this page.
Why is Glyburide Tablet in shortage?
Sanofi-Aventis has made a business decision to permanently stop making their brand of glyburide tablets, sold under the name DiaBeta. This affects all three strengths they made — the 1.25 mg, 2.5 mg, and 5 mg tablets. No specific reason beyond it being a business decision was shared publicly.
It's worth knowing that this report only covers Sanofi-Aventis and their DiaBeta product specifically — it doesn't speak to what other manufacturers may be producing. No dates were provided for when remaining supplies will run out.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Glyburide Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Glyburide Tablet?
Glyburide tablets are currently on the FDA drug-shortage list, so I want to walk you through what this means for you.
This shortage report comes from Sanofi-Aventis, the maker of the brand DiaBeta. It affects all three strengths they make — 1.25 mg, 2.5 mg, and 5 mg — and none of these currently have an available source from this manufacturer. The reason given is a business decision to discontinue making the product. Because this is listed as a discontinuation rather than a temporary delay, this particular supply may not be coming back, which makes a conversation with your prescriber or pharmacist the right next step.
The important thing to know is that this report reflects only one manufacturer. Glyburide is the same medicine no matter who makes it, and other companies are still listed as making all three strengths.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine (glyburide) is reported from makers such as Teva, Avet, and Chartwell, though it may not be in local stock right away.
- If your strength cannot be found, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general national data and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Glyburide Tablet?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Glyburide Tablet is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Glyburide | GLYBURIDE 1.25 mg/1 | Tablet · Oral | Teva Pharmaceuticals USA, Inc. | 00093-8342-01 |
| Glyburide | GLYBURIDE 2.5 mg/1 | Tablet · Oral | Teva Pharmaceuticals USA, Inc. | 00093-8343-01 |
| Glyburide | GLYBURIDE 5 mg/1 | Tablet · Oral | Teva Pharmaceuticals USA, Inc. | 00093-8344-01 |
| Glyburide | GLYBURIDE 5 mg/1 | Tablet · Oral | TEVA Pharmaceuticals USA Inc | 00093-9364-05 |
| Glyburide | GLYBURIDE 2.5 mg/1 | Tablet · Oral | TEVA Pharmaceuticals USA Inc | 00093-9433-05 |
| Glyburide | GLYBURIDE 1.25 mg/1 | Tablet · Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-0056-01 |
| Glyburide | GLYBURIDE 2.5 mg/1 | Tablet · Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-0057-01 |
| Glyburide | GLYBURIDE 5 mg/1 | Tablet · Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-0058-01 |
| Glyburide | GLYBURIDE 2.5 mg/1 | Tablet · Oral | A-S Medication Solutions | 50090-5776-00 |
| Glyburide | GLYBURIDE 5 mg/1 | Tablet · Oral | A-S Medication Solutions | 50090-6196-00 |
| Glyburide | GLYBURIDE 1.25 mg/1 | Tablet · Oral | Chartwell RX, LLC | 62135-0583-30 |
| Glyburide | GLYBURIDE 2.5 mg/1 | Tablet · Oral | Chartwell RX, LLC | 62135-0584-30 |
Therapeutic equivalents & pricing 30 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Glyburide 5 mg | Teva | 100 tablets | $0.064 | AB1 | Availability likely |
| Glyburide 5 mg | TEVA | 100 tablets | $0.064 | AB2 | Availability likely |
| Glyburide 5 mg | Heritage | 100 tablets | $0.064 | AB1 | Availability likely |
| Glyburide 5 mg | Chartwell | 90 tablets | $0.064 | AB1 | Availability likely |
| Glyburide 5 mg | Modavar | 100 tablets | $0.064 | AB1 | Availability likely |
| Glyburide 2.5 mg | Teva | 100 tablets | $0.067 | AB1 | Availability likely |
| Glyburide 2.5 mg | TEVA | 100 tablets | $0.067 | AB2 | Availability likely |
| Glyburide 2.5 mg | Heritage | 100 tablets | $0.067 | AB1 | Availability likely |
| Glyburide 2.5 mg | Chartwell | 30 tablets | $0.067 | AB1 | Availability likely |
| Glyburide 2.5 mg | Modavar | 100 tablets | $0.067 | AB1 | Availability likely |
| Glyburide 1.25 mg | Teva | 100 tablets | $0.067 | AB1 | Availability likely |
| Glyburide 1.25 mg | TEVA | 50 tablets | $0.067 | AB2 | Availability likely |
| Glyburide 1.25 mg | Heritage | 100 tablets | $0.067 | AB1 | Availability likely |
| Glyburide 1.25 mg | Chartwell | 30 tablets | $0.067 | AB1 | Availability likely |
| Glyburide 1.25 mg | Modavar | 100 tablets | $0.067 | AB1 | Availability likely |
| Glyburide 5 mg | Nivagen | 1000 tablets | $0.070 | AB1 | Discontinued |
| Glyburide 2.5 mg | A-S | 30 tablets | — | AB1 | FDA listed |
| Glyburide 2.5 mg | A-S | 30 tablets | — | AB1 | FDA listed |
| Glyburide 2.5 mg | Northwind | 30 tablets | — | AB1 | FDA listed |
| Glyburide 2.5 mg | Proficient | 30 tablets | — | AB1 | FDA listed |
| Glyburide 2.5 mg | Proficient | 30 tablets | — | AB1 | FDA listed |
| glyburide 2.5 mg | Zydus | 100 tablets | — | AB1 | FDA listed |
| Glyburide 2.5 mg | Coupler | 30 tablets | — | AB1 | FDA listed |
| Glyburide 2.5 mg | NuCare | 100 tablets | — | AB1 | FDA listed |
| glyburide 2.5 mg | Zydus | 100 tablets | — | AB1 | FDA listed |
| Glyburide 2.5 mg | REMEDYREPACK | 30 tablets | — | AB1 | FDA listed |
| Glyburide 2.5 mg | Cadila | 100 tablets | — | AB1 | FDA listed |
| Glyburide 2.5 mg | Bryant | 30 tablets | — | AB1 | FDA listed |
| Glyburide 2.5 mg | Nivagen | 1000 tablets | — | AB1 | Discontinued |
| glyburide 1.25 mg | Zydus | 100 tablets | — | AB1 | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Glyburide Tablet — that fall in the same broad treatment class (antihyperglycemic, insulin-release stimulant type) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other endocrinology/metabolism shortages
Glyburide Tablet shortage FAQs
Is Glyburide Tablet in shortage?
Which products are affected?
When will Glyburide Tablet be available again?
Can I still get Glyburide somewhere?
What should I do if I take Glyburide Tablet?
Still have a question about the Glyburide Tablet shortage?
Ask a pharmacist about this shortage →View Glyburide Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.